Aim The aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil HCl, a chemically distinct and specific acetylcholinesterase (AChE) inhibitor for the treatment of Alzheimer's disease, following administration of single oral doses. Methods This was a double-blind, randomized, single-dose, placebo-controlled, sequential-group, ascending-dose study in healthy male volunteers (n=48). Six dose levels were investigated, ranging from 0.3 to 6.0 mg. Donepezil concentrations in plasma were determined by HPLC with UV detection. Pharmacodynamic activity was determined by the radioenzymatic measurement of erythrocyte membrane acetylcholinesterase (rbc-AChE) inhibition. Results The pharmacokinetic disposition of donepezil was observed to be both linear and dose proportional following single-dose administration. The mean peak plasma concentration (C max ) of donepezil was observed at 4.1±1.5 h. The mean terminal disposition half-life was 81.5±22.0 h. The post-absorption phase of the plasma concentration-time curves for the 4.0 mg and 6.0 mg doses appeared to be biphasic, but the rate of donepezil clearance was independent of dose. Plasma concentrations for the 0.3, 0.6 and 0.9 mg dose groups were generally below the level of HPLC detection (2.0 ng ml −1 ), preventing accurate characterization of these doses.
Introduction of Eisai Co. Ltd, Tokyo, Japan) is a new, piperidine-based molecule that is chemically distinct from other cholinesterase It is generally accepted that the symptoms of Alzheimer's disease are related to a cholinergic deficit in the cerebral inhibitors. It is the product of a specific research programme designed to produce an agent selective for the acetylcholincortex and other areas of the brain [1] [2] [3] [4] . The hippocampal formation, in particular, has been shown to play an important esterase (AChE) found in the CNS [6] [7] [8] [9] [10] . Donepezil was shown to improve memory and learning role in the processes of memory and learning [5] . The severity of cholinergic loss in the central nervous system performance in normal rats as well as in rats with experimentally induced cholinergic lesions [11] . Preclinical (CNS) has been found to correlate with both the extent of neuropathology and the severity of cognitive impairment studies indicated that donepezil had markedly greater specificity for brain tissue than physostigmine or tacrine [3] . These findings have led to the development of various classes of agents designed to augment the activity of the [11] . It also had a longer duration of inhibitory action than either of these agents [11] . Thus, it was expected that this surviving cholinergic system in an attempt to improve cognitive function.
high degree of specificity for AChE and very low affinity for plasma cholinesterases would produce central activity The cholinesterase inhibitors have been studied extensively for the treatment of Alzheimer's disease. Donepezil HCl with minimal peripheral cholinergic adverse events. Moreover, unlike acridine-based cholinesterase inhibitors such as tacrine [11, 12] , donepezil is not compromised by
In controlled phase II and III clinical studies of up to 6 position (>45°angle from supine) for 4 h after drug administration, after which they were allowed food. Subjects months' duration, donepezil (5 and 10 mg day −1 ) produced significant improvement in cognitive and global function in stayed at the investigational site for an additional 6 days until all of the follow-up assessments had been completed. During patients with mild to moderately severe Alzheimer's disease [13, 14, 16] . Furthermore, additional clinical trials indicate this time, they abstained from caffeine-containing beverages, and physical exertion was limited to normal walking. that these clinical improvements are maintained, relative to untreated historical control subjects, during long-term treatment (over 2 years) [15] .
Sample collection and analysis The purpose of the present study was to characterize the pharmacokinetic and pharmacodynamic profiles associated Venous blood samples for the measurement of donepezil concentrations and AChE activity were collected at 30-min with the administration of single oral doses of donepezil in healthy volunteers.
intervals for the first 4 h post-dose, and then at 6, 8, 12, 18, 24 and 36 h. Thereafter, blood samples were taken once daily (48, 72, 96 and 120 h post-dose). A final sample was Methods taken on day 8 (144 h). Samples were placed on ice immediately upon collection.
Subjects
Characterization of donepezil pharmacokinetics was performed by analysing plasma separated from the cellular The study population comprised 48 healthy, ambulatory, non-smoking adult male volunteers, between 19 and 41 years components by centrifugation and stored at −20°C until analysis. Plasma donepezil concentrations were measured using of age. Their body weight ranged between 65.0 and 85.9 kg, and all were within 15% of ideal weight based on the a specific and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection [17] . Metropolitan Insurance Company Height and Weight Tables  (1983) . Upon clinical examination, subjects were found to
The lowest quantifiable concentration was 2.0 ng ml
. be free from significant hepatic, gastrointestinal, renal, respiratory, endocrine, haematological, neurological, psychiPharmacokinetic analysis atric or cardiovascular system abnormalities. None had a known or suspected history of alcohol or drug abuse, and
Model-independent pharmacokinetic parameters were determined using standard techniques. The peak plasma concennone had taken over-the-counter medications or consumed alcoholic beverages for at least 48 h prior to enrolment. No tration (C max ) and the time at which the peak concentration occurred (t max ) were determined by inspection of individual investigational or prescription medications had been taken within 1 month of entry into the study. subject data. For subjects with more than one peak, t max was defined as the time at which the highest peak occurred. This study was conducted in accordance with the principles stated in the Declaration of Helsinki. The protoIf the multiple peaks were the same height, then t max was defined for the first peak. A terminal disposition rate col was approved by the Institutional Review Board for Investigations Involving Human Subjects, Harris constant (l z ) was calculated by linear least-squares regression of the log-transformed plasma concentration-time data in Laboratories, Lincoln, Nebraska, USA, and all subjects gave written informed consent prior to participation. the terminal disposition phase. The slope of the terminal disposition phase was calculated from the first time point at which there was no systematic deviation from log-linear Protocol decline in plasma concentration to the last quantifiable measurement. The terminal half-life (t D ) was calculated as The study was of a double-blind, randomized, placebocontrolled, single-dose, sequential-group design. Donepezil 0.693/l z .
The area under the plasma concentration-time curve was administered in single oral doses according to an ascending-dose scheme. The selection of doses (0.3, 0.6, (AUC), for the time (t) at which the final measurable concentration was obtained (AUC (0-t) ), was calculated by 0.9, 2.0, 4.0 and 6.0 mg), which was based upon results from phase I studies conducted in Japan, included doses the linear trapezoidal rule. The AUC from the final time point to time infinity was estimated as the ratio of the final below and within the range anticipated to be clinically effective. measurable concentration to l z . The total area under the concentration-time curve (AUC (0-2 ) ) was calculated by Groups of eight subjects were assigned to each dose level. Within each dose group, two subjects were randomized to addition of AUC (0-t) and AUC (t-2 ) . Time-averaged total body clearance (CL T /F) was calculated as the ratio of the receive placebo and six to receive donepezil. Progression to the next higher dose was contingent upon demonstration administered dose (D) to AUC (0-2 ) , where the factor F accounts for bioavailability (D/AUC (0-2 ) ·F). The apparent that the previous dose was well tolerated. Baseline measurements were taken on study day 1 and the study medication volume of distribution ( V lz /F) was estimated as the ratio of CL T /F to l z . was taken on study day 2.
The trial was blinded by using a standard dose of three tablets per patient. The dose consisted of donepezil (0.3 mg Pharmacodynamic assessments or 2.0 mg tablets) and/or placebo tablets, the number of each being determined by dose group and randomization
The pharmacodynamic activity of donepezil was examined by measuring AChE activity in peripheral erythrocyte code. The tablets were taken with 250 ml of tap water after an 8-h fast. The subjects remained awake and in an upright membranes (rbc-AChE) taken from the samples used for the pharmacokinetic determinations. Following the removal inhibition versus concentration profiles within a given dose group, analysed singly or pooled across the dose group. The of the plasma for donepezil measurements, the white blood cell/platelet layer and the top 3 mm of erythrocytes (rbc) relationship between plasma donepezil concentration and AChE inhibition was defined using orthogonal least-squares were extracted, using a Pasteur pipette. The remaining rbcs were gently vortexed before being transferred to a polypropregression analysis.
Fisher's exact test using two-sided P values was used to ylene Sarstedt storage tube which was stored in an upright position at −20°C until analysis.
compare the incidence of adverse events in the pooled placebo group with that in each donepezil group. Results To measure AChE activity, a specific and sensitive radioenzyme method was developed in which [ 3 Hof haematology, clinical chemistry and routine urinalysis tests were compared with normal ranges, and shift tables acetyl]choline was incubated at 4°C with homogenized rbc containing unknown concentrations of donepezil [18] . After were used to identify trends in the data. 30 s, the hydrolytic product was extracted into a scintillation cocktail and total radioactivity was counted. Activity from Results subject samples was quantified using standard curves of percentage rbc-AChE inhibition versus the natural logarithm Subjects of the donepezil concentration (ng g −1 erythrocytes). The curves were fit using a third-order polynomial equation.
The demographic data for the study population are summarized in Table 1 . The dose groups were well balanced The inter-day precision of this assay was 7.4%. Intra-subject circadian variability in AChE activity was 2.6%. Parameters with respect to age, height and weight. All of the subjects assigned to treatment with donepezil were Caucasian. The calculated were maximal AChE inhibition ( peak effect), the time at which it occurred, and the area under the effect placebo-treated subjects included two black volunteers and two of other ethnic origin. A total of 48 subjects were curve (AUE) from time 0 to time t (AUE (0-t ) ).
enrolled in the study, and all 48 subjects completed the study without incident.
Safety assessments
All adverse events spontaneously reported by a subject or Pharmacokinetics elicited/observed by the investigator were recorded, together with times of onset and cessation, and an assessment of Plasma concentrations of donepezil in the subjects receiving the 0.3, 0.6 and 0.9 mg doses were below the validseverity and causality.
Vital signs were measured at specified times during the ated limit of HPLC quantification (2.0 ng ml −1 ). Pharmacokinetic evaluation was therefore confined to the 2.0, 4.0 course of the study. Blood pressures were measured according to the American Heart Association recommendaand 6.0 mg dose groups. Peak plasma concentrations of donepezil were achieved tions. The point of disappearance of Korotkoff sounds ( phase V) was recorded as the diastolic blood pressure. approximately 4 h after administration of all three doses (Table 2 ). Mean peak concentrations of donepezil increased Routine haematology, clinical chemistry and urinalysis were undertaken following an 8-h fast on days 4 and 8.
proportionately with increasing dose. The AUC (0-2 ) values also suggested dose proportionality (Table 2) . DoseHaematological assessments included haemoglobin, haematocrit, rbc count, platelet count, white blood cell count normalized C max did not differ significantly across the range studied. and differential. Clinical chemistry comprised assessment of liver function (alanine transaminase, aspartate transaminase, The clearance of donepezil remained fairly constant at all three dose levels. The plasma concentration-time curves for alkaline phosphatase, total bilirubin), renal function (creatinine, blood urea nitrogen), metabolic status (glucose, total the 4.0 and 6.0 mg dose levels showed characteristics of biphasic elimination, with the initial disposition phase being protein, albumin, cholesterol, triglycerides), electrolytes (sodium, potassium, chloride, phosphorus, calcium), and complete within the first 24 h after drug administration ( Figure 1 ). The disposition of the 2.0 mg dose group could cardiac enzymes (lactate dehydrogenase and creatine kinase). Routine urinalysis was performed ( pH, glucose, protein, not be adequately characterized because the plasma concentrations of donepezil approached the assay quantification haemoglobin or blood, ketones), together with specific gravity and microscopic examination of the urine sediment. the fact that there was a dose-proportional increase in mean C max from 6.9 to 11.6 ng ml −1 .
AChE inhibition lasted less than 24 h in the 2.0 mg dose group. However, the extent of rbc-AChE inhibition declined more gradually in the 4.0 mg and 6.0 mg dose groups, and, on average, remained above 10% for 72 h after donepezil administration (Figure 2) . The rapid reversibility of donepezil-mediated inhibition of rbc-AChE is supported by the lack of hysteresis in the relationship between AChE inhibition and plasma concentration of donepezil ( Figure 2) .
As shown in Figure 3 , there was a linear relationship between the area under the effect-time profile (AUE (0-t) ) and AUC (0-t) . The AUE (0-t) /AUC (0-t ) ratio was independent of dose, but at the 4.0 mg and 6.0 mg dose levels there was significant positive correlation between the extent of rbcAChE inhibition and plasma donepezil concentration groups of six healthy male volunteers. Safety limit (2.0 ng ml −1 ) by 24 h (Figure 1) . Consequently, the Donepezil was well tolerated by all subjects with no terminal half-life (t D ) appeared to be shorter in subjects clinically significant changes in laboratory, ECG or vital sign receiving the 2 mg dose (mean 53.8 h) than in those parameters observed at any dose. Adverse events that were receiving the two higher doses (means 82.8 and 80.1 h, spontaneously reported or observed by the investigator respectively). The same assay limitations are the most likely included nausea, diarrhoea, insomnia, vomiting and fatigue. explanation for the observed differences in V lz /F (Table 2) .
These were all mild in intensity and transient. The difference in the incidence of adverse events between donepezil-and Pharmacodynamics placebo-treated subjects within each dose group was not statistically significant ( P >0.05, Fisher's exact test). Seventeen of the 18 subjects in the 2.0, 4.0 and 6.0 mg dose groups showed some degree of rbc-AChE inhibition. A single subject in whom no measurable rbc-AChE inhibition Discussion was observed had aberrantly low baseline AChE activity.
The results of this study demonstrate that the pharmacoPeak rbc-AChE inhibition was observed within 4 h of kinetics of donepezil are linear over the 2-6 mg dose range, administration of the 2.0, 4.0 and 6.0 mg doses of donepezil as shown by the relationship between dose, C max and (Table 3 ) and coincided with the t max in plasma. Lower AUC (0-2 ) . The results also indicate that donepezil is doses of donepezil showed no evidence of pharmacodynamic absorbed from the gastrointestinal tract at a moderate rate, activity. Mean maximal AChE inhibition ( E max ; 33-35%) with peak concentrations occurring approximately 4 h after was comparable in the 4.0 and 6.0 mg dose groups, despite drug administration. Based on the data obtained at the 4.0 mg and 6.0 mg half-life of donepezil is not indicative of irreversible enzyme physostigmine (IC 50 ratio: 11.9) or tacrine (IC 50 ratio: 0.9) [11] . Furthermore, a study investigating the tissue distribution of cholinesterase inhibition in aged rats has shown that donepezil is specific for AChE in the brain [19] . In this study, the maximal degree of enzyme inhibition achieved after single 4.0 mg or 6.0 mg doses of donepezil was on the order of 35%. Ex vivo studies in patients with Alzheimer's disease have shown that the maximal pharmacodynamic effect of donepezil (approximately 70% inhibition) occurs in a cumulative fashion over the first 2-3 weeks of long-term administration, consistent with the achievement of steady state in plasma after the same period [20] . Donepezil was well tolerated by the healthy men in this study and there were no dose-dependent or clinically significant changes in any of the safety variables. The incidence of adverse events was comparable with that in placebo-treated subjects and there was no evidence of hepatotoxicity as measured by standard liver function tests, suggesting that the specificity for AChE may indeed reduce the incidence of peripheral cholinergic side-effects. Indeed, in over 400 000 patient-days of drug exposure in the clinical development programme, other than transient gastrointestinal complaints, there have been no specific adverse events performed in Japan [21, 22] and suggest that the doseproportional pharmacokinetic and pharmacodynamic profile of donepezil seen in this study will provide the basis for a inhibition, but suggests that the drug is released slowly from its target enzyme or from other binding sites.
predictable and specific clinical response in patients with Alzheimer's disease. Its long half-life, which allows onceDonepezil resulted in a relatively rapid and prolonged inhibition of rbc-AChE activity. The AUE for enzyme daily dosing, and its apparent lack of hepatotoxicity at pharmacodynamically effective doses suggest that donepezil inhibition was directly dependent on the AUC of donepezil in plasma. Maximal rbc-AChE inhibition coincided with may be used safely and conveniently in the treatment of Alzheimer's disease. the C max in plasma (i.e. 4 h) and the duration of rbc-AChE inhibition coincided with the long half-life of donepezil. Measurable (>10%) enzyme inhibition persisted for up to
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In preclinical studies, donepezil demonstrated greater NE 68501, USA, who conducted this clinical trial, and Harris Laboratories Institutional Review Board, who specificity for rat brain AChE than plasma butyrylcholinesterase (BuChE) (IC 50 ratio BuChE/AChE: 1252) than either reviewed and approved the study and protocol.
